Lipofen

From WikiCover

Lipofen is a novel, patented formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia, a cholesterol disorder. Hyperlipidemia is a condition characterized by high levels of low-density lipoprotein (LDL) cholesterol and/or triglycerides (a type of fat found in the blood). Fenofibrate is known to lower triglycerides and LDL cholesterol and increase high-density lipoproteins (HDL), known as good cholesterol.

Lipofen received FDA approval for three unique fenofibrate dosages: 50, 100 and 150 mg, with the 150 mg strength equivalent to Tricor 160 mg under fed conditions. With Lipofen, the extent of absorption is increased under high-fat conditions relative to low-fat conditions.

On July 10, 2007, Cipher Pharmaceuticals announced that it has entered into a definitive licensing and distribution agreement with ProEthic Pharmaceuticals under which Cipher has granted ProEthic the exclusive right to market, sell and distribute Lipofen in the United States, its territories and possessions.